Show simple item record

dc.contributor.authorPurroy Garcia, Francisco
dc.contributor.authorGarcía, Cristina
dc.contributor.authorMauri-Capdevila, Gerard
dc.contributor.authorPereira, Cristina
dc.contributor.authorTorres-Querol, Coral
dc.contributor.authorVazquez-Justes, Daniel
dc.contributor.authorVicente-Pascual, Mikel
dc.contributor.authorVena Martínez, Ana Belén
dc.contributor.authorArque, Gloria
dc.description.abstractBackground: Remote ischemic conditioning during cerebral ischemia (remote ischemic perconditioning, RIPerC) refers to the application of several cycles of brief ischemia and reperfusion (I/R) commonly to a limb, and it represents a new paradigm in neuroprotection with multiple mechanisms of action in ischemic stroke (IS) patients during acute phase. Some clinical trials just finished, and a few others are still ongoing; gather the current knowledge and pull it down to influence the present and future studies was the goal of this paper. Methods: A systematic review of published research papers and/or registered clinical trials since 2000 was performed. Results: Nineteen studies were identified and only four studies were completed. All of them have demonstrated that RIPerC is safe, feasible and well tolerated in IS patients. However, a high heterogeneity of clinical trial characteristics was observed: five (26.3%) randomized clinical trials (RCTs) included only thrombolytic-treated patients, three (15.8%) RCTs only thrombectomy-treated patients, and five (26.3%) RCTs required radiological confirmation of IS. Temporal inclusion criteria vary from 4 h to 48 h. Most of the clinical trials used 4 cycles of RIPerC in the upper non-affected limb. Interestingly, only three (16.7%) RCTs applied RIPerC during the transportation in the ambulance. Neuroimaging outputs were the main endpoints when endovascular therapy was applied; functional outcome is also the main endpoint in large-medium size studies. Conclusions: This review summarizes the completed and ongoing clinical trials on RIPerC in IS patients, where RIPerC has been used alone or in combination with recanalization therapies. Ongoing clinical trials will provide new information on the best RIPerC intervention strategy and potentially improve the functional outcome of IS patients; definition of new RIPerC strategies would ideally aim at enhancing tissue preservation, promoting neurological recovery, and stratify patients to improve treatment feasibility.ca_ES
dc.description.sponsorshipThis study was supported by the Government of Catalonia-Agència de Gestió d’Ajuts Universitaris i de Recerca (FP: 2017 SGR 1628), Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “A way to make Europe”) (FP: Project PI17–01725) and the INVICTUS plus Research Network (Carlos III Health Institute).ca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofBMC Neurology, 2020, vol. 20, núm. 266ca_ES
dc.rightscc-by (c) Purroy Garcia, Francisco et al., 2020ca_ES
dc.subjectIschemic strokeca_ES
dc.subjectRemote ischemic perconditioningca_ES
dc.subjectRandomized clinical trialsca_ES
dc.subjectSystematic reviewca_ES
dc.titleInduced neuroprotection by remote ischemic perconditioning as a new paradigm in ischemic stroke at the acute phase, a systematic reviewca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c) Purroy Garcia, Francisco et al., 2020
Except where otherwise noted, this item's license is described as cc-by (c) Purroy Garcia, Francisco et al., 2020